Affiliation:
1. Qingdao Women and Children's Hospital
2. Chongqing Medical University
3. Xi’an Ninth Hospital
4. Navy Qingdao Special Service Recuperation Center
5. Medicial College of Qingdao University，Qingdao 266000
Abstract
Abstract
The pathogenesis of endometrial cancer (EC) remains unclear. Currently, there is a lack of available drugs that specifically target EC. Here, we demonstrated that both DBC1 and SIRT1 as oncogenic factors were involved in the development and progression of EC and associated with histological grade, lymph node metastasis, depth of myometrial invasion and FIGO stage, the protein interaction ability of DBC1 and SIRT1 in cancer group decreased compared with the control group, and tanshinone IIA promoted apoptosis and inhibited proliferation of Ishikawa cells through P53-Cleaved caspase-3 pathway and Bcl-2 pathway, a process possibly regulated by CK2/DBC1/SIRT1/P53 signaling pathway. In the xenograft model of Ishikawa origin, high-concentration tanshinone IIA also down-regulated the expression of DBC1 and SIRT1, and inhibited the growth of tumors. Our results indicate that DBC1 and SIRT1 may serve as novel molecular targets and tanshinone IIA may play a role in the treatment of EC.
Publisher
Research Square Platform LLC
Reference44 articles.
1. Altin D,Şükür YE,et al.Extrapelvic Sentinel Lymph Nodes in Endometrial Cancer Patients With Unmapped Pelvic Side:A Brief Report[J];Taşkin S;Int J Gynecol Cancer,2018
2. Cancer statistics,2014[J];Siegel RMJ;CA Cancer J Clin,2014
3. Tanshinone IIA pretreatment protects myocardium against ischaemia/reperfusion injury through the phosphatidylinositol 3-kinase/Akt-dependent pathway in diabetic rats[J];Zhang Y;Diabetes Obes Metab,2010
4. SH,et al.TanshinoneIIA suppress the proliferation of HNE-1 nasopharyngeal carcinoma an in vitro study[J];Zhou M;Saudi J Biol Sci,2018
5. Changyu Shan,Lei Liu,Tanshinone IIA inhibits HIF-1α and VEGF expression in breast cancer cells via mTOR/p70S6K/RPS6/4E-BP1 signaling pathway[J];Li G;PLos One 2017